Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Allocetra (Immunotherapy) in Knee osteoarthritis. The expected timing is based on the latest available company guidance and may change.
3/3/25- Interim Ph1 6-month efficacy data. 4/21/25- Completed enrollment of all patients. 6/10/25- Poster presentation at EULAR 25. 8/18/25- 3-month topline data presented. 11/24/25- 6-month topline data reported. 03/23/26:- FDA cleared IND for Allocetra in knee OA; enables global Ph2b initiation; first patient enrollment planned. 03/25/26:- Allocetra clinical programs continue progressing, with primary focus on age-related osteoarthritis and improving mobility; no new milestones. 04/21/26:- DKMA granted CTA for global Ph2b knee OA trial; enrollment planned in U.S., Denmark, Poland. 04/23/26:- Ph2a NCT06233474 3- and 6-month KOA data to be presented at OARSI April 24-25, 2026. 05/18/26:- First patient dosed at a United States site in global Ph2b knee OA trial. 06/01/26:- Ph2a NCT06233474 3- and 6-month KOA data presented at EULAR June 3, 2026. 07/13/26:- FDA granted RMAT for Allocetra knee OA. Type B FDA meeting planned. Ph2b topline expected Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.